Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Genitourinary 1Dermatologic 1Breast 1

Conditions

Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 1Head and Neck Neoplasms 1Depression 1

Interventions

Cisplatin 315Radiotherapy 139Cetuximab 133pembrolizumab 131Docetaxel 122Carboplatin 119Radiotherapy, Intensity-Modulated 97Fluorouracil 94Paclitaxel 92Nivolumab 64Gemcitabine 50toripalimab 46Radiation 44Drug Therapy 39Capecitabine 39Magnetic Resonance Spectroscopy 38Surgical Procedures, Operative 33camrelizumab 31130-nm albumin-bound paclitaxel 29apatinib 27tislelizumab 26Chemoradiotherapy 26Specimen Handling 25Bevacizumab 24durvalumab 23Albumin-Bound Paclitaxel 23nimotuzumab 22lenvatinib 21Sorafenib 21Platinum 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Venlafaxine Hydrochloride × Head & Neck × Clear all
NCT03574792 2026-04-16

Gabapentin, Methadone, and Oxycodone With or Without Venlafaxine Hydrochloride in Managing Pain in Participants With Stage II-IV Squamous Cell Head and Neck Cancer Undergoing Chemoradiation Therapy

Roswell Park Cancer Institute

Phase 2 Completed
62 enrolled 10 charts
DermatologicHead & Neck

Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8

NCT05724849 2024-01-18

Venlafaxine for the Prevention of Depression in Patients With Head and Neck Cancer

Vanderbilt University Medical Center

Phase 2 Withdrawn
Head & Neck

Depression, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡